Y2020 Phase 2 clinical trials for AL102-PDT have been started

Y2020 Phase 2A clinical trials for AL101-OME have been started

Y2019 Phase 2A clinical trials for AL101-NASH have been started

Y2019 MOU on PASylation with XL-protein was signed

Y2018 Phase 2 clinical trials for AL101-AMD have been started

Y2018 Approval from KFDA on the revised IND for Phase 2 clinical trial of AL101-AMD was given

Y2018 Sales for Ob-X have been launched at home-shopping channels

Y2016 Listed in KONEX

Y2013 ~ Y2016 12 billion won was totally raised from venture capital firms

Y2015 Approval from KFDA on the IND of Phase 2 clinical trial of AL101-AMD for wet AMD was given

Y2013 Approval from KFDA on the IND of Phase 3 clinical trial of AL101-AOB for abdominal obesity was given

Y2012 Sales of Ob-X have begun

Y2010 Ob-X has been approved from KFDA as a specific health functional food with proven claims of visceral fat reduction

Y2009 Completed Phase 2 clinical trial of AL101-AOB for abdominal obesity

Y2007 Awarded INNO-BIZ certification from SMBA

Y2006 Attracted capital from KDB for technology development

Y2005 Selected as 'Excellent Company' from Korea Technology and Credit Guarantee agency

Y2004 ~ Y2009 Awarded numerous research grants from the Ministry of Health & Welfare and SMBA for developing new drugs

Y2000 Research center was certified

Y1999 Recognized as a start-up with good technology